In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder

NeuroImage

Volumn 42, Issue 1, 2008, Pages 306-314

  Perani, Daniela ^a,b,c   Garibotto, Valentina ^a,b   Gorini, Alessandra ^a   Moresco, Rosa Maria ^b,d,e   Henin, Marta ^c   Panzacchi, Andrea ^b   Matarrese, Mario ^d   Carpinelli, Assunta ^d   Bellodi, Laura ^a,b,c   Fazio, Ferruccio ^b,d,e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c National Institute of Neuroscience   (Italy)

^d INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

5HT2A; D2; Dopamine; Obsessive compulsive disorder; PET; Serotonin

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; RACLOPRIDE C 11; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; FRONTAL CORTEX; HUMAN; IN VIVO STUDY; MALE; NEUROMODULATION; OBSESSIVE COMPULSIVE DISORDER; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY;

ADULT; BRAIN; FEMALE; HUMANS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 45849150005     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.04.233     Document Type: Article

References (60)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (1994), American Psychiatric Association, Washington, DC
2. Adams K.H., Hansen E.S., Pinborg L.H., Hasselbalch S.G., Svarer C., Holm S., Bolwig T.G., and Knudsen G.M. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int. J. Neuropsychopharmacol. 8 (2005) 391-401
3. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., Minoshima S., Kilbourn M.R., and Frey K.A. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61 (2003) 310-315
4. Bechara A., Damasio A.R., Damasio H., and Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50 (1994) 7-15
5. Brody A.L. Functional brain imaging of tobacco use and dependence. J. Psychiatr. Res. 40 (2006) 404-418
6. Cahir M., Ardis T., Reynolds G.P., and Cooper S.J. Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT 2A receptor binding in the rat. Psychopharmacology (Berl) 190 (2007) 497-506
7. Carmin C.N., Wiegartz P.S., Yunus U., and Gillock K.L. Treatment of late-onset OCD following basal ganglia infarct. Depress. Anxiety 15 (2002) 87-90
8. Cavedini P., Bassi T., Zorzi C., and Bellodi L. The advantages of choosing antiobsessive therapy according to decision-making functioning. J. Clin. Psychopharmacol. 24 (2004) 628-631
9. Coetzer B.R. Obsessive-compulsive disorder following brain injury: a review. Int. J. Psychiatry Med. 34 (2004) 363-377
10. Dell'Osso B., Allen A., and Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin. Pharmacother. 6 (2005) 2727-2740
11. Delorme R., Betancur C., Callebert J., Chabane N., Laplanche J., Mouren-Simeoni M., Launay J., and Leboyer M. Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder. Neuropsychopharmacology 30 (2005) 1539-1547
12. Denys D., Zohar J., and Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry 65 Suppl 14 (2004) 11-17
13. Denys D., van der Wee N., Janssen J., De Geus F., and Westenberg H.G.M. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 55 (2004) 1041-1045
14. el Mansari M., Bouchard C., and Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 13 (1995) 117-127
15. Enoch M.A., Kaye W.H., Rotondo A., Greenberg B.D., Murphy D.L., and Goldman D. 5-HT2A promoter polymorphism-1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet 351 (1998) 1785-1786
16. Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Fazio F., and Perani D. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann. Neurol. 57 (2005) 216-225
17. Friedlander L., and Desrocher M. Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clin. Psychol. Rev. 26 (2006) 32-49
18. Garnett E.S., Firnau G., and Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 305 (1983) 137-138
19. Goodman W.K., McDougle C.J., Price L.H., Riddle M.A., Pauls D.L., and Leckman J.F. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?. J. Clin. Psychiatry 51 (1990) 36-43 Suppl
20. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch. Gen. Psychiatry 46 (1989) 1012-1016
21. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch. Gen. Psychiatry 46 (1989) 1006-1011
22. Gray J.A., and Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res. Bull. 56 (2001) 441-451
23. Gunn R.N., Lammertsma A.A., Hume S.P., and Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6 (1997) 279-287
24. Guy W. ECDEU assessment manual for psychopharmacology, revised, Rockville, MD: US Department of Health, Education and Welfare (1976)
25. Hasselbalch S.G., Hansen E.S., Jakobsen T.B., Pinborg L.H., Lønborg J.H., and Bolwig T.G. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatr. Scand. 115 (2007) 388-394
26. Hesse S., Muller U., Lincke T., Barthel H., Villmann T., Angermeyer M.C., Sabri O., and Stengler-Wenzke K. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 140 (2005) 63-72
27. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazziti D., Rasmussen S.A., Ravizza L., Benkelfat C., Saxena S., Greenberg B.D., Sasson Y., and Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry 63 Suppl 6 (2002) 20-29
28. Insel T.R. Toward a neuroanatomy of obsessive-compulsive disorder. Arch. Gen. Psychiatry 49 (1992) 739-744
29. Ito H., Nyberg S., Halldin C., et al. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J. Nucl. Med. 39 (1998) 208-214
30. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., Brooks D.J., Bench C.J., and Grasby P.M. Evidence for striatal dopamine release during a video game. Nature 393 (1998) 266-268
31. Lammertsma A.A., Bench C.J., Hume S.P., Osman S., Gunn K., Brooks D.J., and Frackowiak R.S. Comparison of methods for analysis of clinical [11C]raclopride studies. J. Cereb. Blood Flow Metab. 16 (1996) 42-52
32. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
33. Lochner C., Hemmings S.M., Kinnear C.J., Niehaus D.J., Nel D.G., Corfield V.A., Moolman-Smook J.C., Seedat S., and Stein D.J. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr. Psychiatry 46 (2005) 14-19
34. Lucignani G., Gobbo C., Moresco R., Antonini A., Panzacchi A., Bonaldi L., Carpinelli A., Caraceni T., and Fazio F. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-b-carbomethoxy-3-b-(4-fluorophenyl)-tropane in patients with movement disorders. Nucl. Med. Commun. 23 (2002) 1047-1055
35. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., and Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21 (2001) 1034-1057
36. Meira-Lima I., Shavitt R.G., Miguita K., Ikenaga E., Miguel E.C., and Vallada H. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Genes Brain Behav. 3 (2004) 75-79
37. Montague P.R., Hyman S.E., and Cohen J.D. Computational roles for dopamine in behavioural control. Nature 431 (2004) 760-767
38. Moresco R.M., Pietra L., Henin M., Panzacchi A., Locatelli M., Bonaldi L., Carpinelli A., Gobbo C., Bellodi L., Perani D., and Fazio F. Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naive patients. Neuropsychopharmacology 32 (2007) 197-205
39. Pappata S., Dehaene S., Poline J.B., Gregoire M.C., Jobert A., Delforge J., Frouin V., Bottlaender M., Dolle F., Di Giamberardino L., and Syrota A. In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. Neuroimage 16 (2002) 1015-1027
40. Pauls D.L., Towbin K.E., Leckman J.F., Zahner G.E., and Cohen D.J. Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Arch. Gen. Psychiatry 43 (1986) 1180-1182
41. Pauls D.L., Alsobrook II J.P., Goodman W., Rasmussen S., and Leckman J.F. A family study of obsessive-compulsive disorder. Am. J. Psychiatry 152 (1995) 76-84
42. Pitman R.K. Animal models of compulsive behavior. Biol. Psychiatry 26 (1989) 189-198
43. Pogarell O., Hamann C., Popperl G., Juckel G., Chouker M., Zaudig M., Riedel M., Moller H.J., Hegerl U., and Tatsch K. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol. Psychiatry 54 (2003) 1406-1413
44. Pujol J., Soriano-Mas C., Alonso P., Cardoner N., Menchon J.M., Deus J., and Vallejo J. Mapping structural brain alterations in obsessive-compulsive disorder. Arch. Gen. Psychiatry 61 (2004) 720-730
45. Rack M., and Chir D. Experience with intravenous clomipramine. In: Geigy (Ed). Obsessional states and their treatment with anafranil (1970) 10-13
46. Reimold M., Smolka M.N., Zimmer A., Batra A., Knobel A., Solbach C., Mundt A., Smoltczyk H.U., Goldman D., Mann K., Reischl G., Machulla H., Bares R., and Heinz A. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity- a [(11)C]DASB PET study. J. Neural Transm. 114 (2007) 603-609
47. Robbins T.W., and Everitt B.J. Functions of dopamine in the dorsal and ventral striatum. Semin. Neurosci. 4 (1992) 119-127
48. Roth R.M., Baribeau J., Milovan D.L., and O'Connor K. Speed and accuracy on tests of executive function in obsessive-compulsive disorder. Brain Cogn. 54 (2004) 263-265
49. Schotte A., Maloteaux J.M., and Laduron P.M. Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res. 276 (1983) 231-235
50. Sheenhan D., Lecrubier Y., Janavs J., Knapp E., and Weiller E. MINI International Neuropsychiatric Interview (1994)
51. Sheline Y.I., Mintun M.A., Moerlein S.M., and Snyder A.Z. Greater loss of 5-HT(2A) receptors in midlife than in late life. Am. J. Psychiatry 159 (2002) 430-435
52. Simpson H.B., Lombardo I., Slifstein M., Huang H.Y., Hwang D.R., Abi-Dargham A., Liebowitz M.R., and Laruelle M. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol. Psychiatry 54 (2003) 1414-1421
53. Stengler-Wenzke K., Müller U., Angermeyer M.C., Sabri O., and Hesse S. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur. Arch. Psychiatry Clin. Neurosci. 254 (2004) 252-255
54. Sturm V., Lenartz D., Koulousakis A., Treuer H., Herholz K., Klein J.C., and Klosterkotter J. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J. Chem. Neuroanat. 26 (2003) 293-299
55. Tizabi Y., Louis V.A., Taylor C.T., Waxman D., Culver K.E., and Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol. Psychiatry 51 (2002) 164-171
56. van der Wee N.J., Stevens H., Hardeman J.A., Mandl R.C., Denys D.A., van Megen H.J., Kahn R.S., and Westenberg H.M. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am. J. Psychiatry 161 (2004) 2201-2206
57. Walitza S., Wewetzer C., Warnke A., Gerlach M., Geller F., Gerber G., Görg T., Herpertz-Dahlmann B., Schulz E., Remschmidt H., Hebebrand J., and Hinney A. 5-HT2A promoter polymorphism-1438G/A in children and adolescents with obsessive-compulsive disorders. Mol. Psychiatry 7 (2002) 1054-1057
58. Whiteside S.P., Port J.D., and Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 132 (2004) 69-79
59. Wong D.F., Brašić J.R., Singer H.S., Schretlen D.J., Kuwabara H., Zhou Y., Nandi A., Maris M.A., Alexander M., Ye W., Rousset O., Kumar A., Szabo Z., Gjedde A., and Grace A.A. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette Syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 33 (2008) 1239-1251
60. Zitterl W., Aigner M., Stompe T., Zitterl-Eglseer K., Gutierrez-Lobos K., Schmidl-Mohl B., Wenzel T., Demal U., Zettinig G., Hornik K., and Thau K. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 32 (2007) 1661-1668